Lest I ask you to rely on my opinion, I wanted to close today’s email with a brilliant commentary/editorial from many of the big names in advanced prostate cancer. This short article is a quick but brilliant read so I encourage any of you who treat advanced prostate cancer to take the time to go through these authors summary of the data.
Lest I ask you to rely on my opinion, I wanted to close today’s email with a brilliant commentary/editorial from many of the big names…
Men at a high genetic risk adhering to a healthy lifestyle had a reduced risk of lethal prostate cancer compared with men at a high…
We present the rationale for keeping the “cancer” label for grade group 1 (GG1) prostate cancer. Maintaining GG1 as the lowest grade outweighs the potential…
The obturator nerve can be damaged during urological or gynecological surgeries. Obturator nerve injury is a preventable complication for which there are different management options,…
Climate-smart actions in the operating room (OR) are urgently needed and deserve more awareness and implementation. Although some actions are mainly the role of stakeholders,…
Repeated, prostate-specific antigen–based screening with a 4-yr interval in men aged 55–69 yr reduces prostate cancer–specific mortality and metastatic prostate cancer after a median follow-up…
In this clinical trial, we investigated a novel noninvasive treatment option of stereotactic radiation therapy for the treatment of primary kidney cancer. We found that…
In patients with oligometastatic renal cell carcinoma, radiotherapy to all metastases followed by short-course pembrolizumab is safe, with a grade 3 adverse event rate of…
In patients with oligometastatic renal cell carcinoma, radiotherapy to all metastases followed by short-course pembrolizumab is safe, with a grade 3 adverse event rate of…
